<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38405753</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Characteristics and Determinants of Pulmonary Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.02.13.24302781</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.02.13.24302781</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Persistent cough and dyspnea are prominent features of post-acute sequelae of SARS-CoV-2 (termed 'Long COVID'); however, physiologic measures and clinical features associated with these pulmonary symptoms remain poorly defined.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Using longitudinal pulmonary function testing (PFTs) and CT imaging, this study aimed to identify the characteristics and determinants of pulmonary Long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The University of Alabama at Birmingham Pulmonary Long COVID cohort was utilized to characterize lung defects in patients with persistent pulmonary symptoms after resolution primary COVID infection. Longitudinal PFTs including total lung capacity (TLC) and diffusion limitation of carbon monoxide (DLCO) were used to evaluate restriction and diffusion impairment over time in this cohort. Analysis of chest CT imaging was used to phenotype the pulmonary Long COVID pathology. Risk factors linked to development of pulmonary Long COVID were estimated using univariate and multivariate logistic regression models.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Longitudinal evaluation 929 patients with post-COVID pulmonary symptoms revealed diffusion impairment (DLCO &#x2264;80%) and restriction (TLC &#x2264;80%) in 51% of the cohort (n=479). In multivariable logistic regression analysis (adjusted odds ratio; aOR, 95% confidence interval [CI]), invasive mechanical ventilation during primary infection conferred the greatest increased odds of developing pulmonary Long COVID with diffusion impaired restriction (aOR=10.9 [4.09-28.6]). Finally, a sub-analysis of CT imaging identified evidence of fibrosis in this population.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Persistent diffusion impaired restriction was identified as a key feature of pulmonary Long COVID. Subsequent clinical trials should leverage combined symptomatic and quantitative PFT measurements for more targeted enrollment of pulmonary Long COVID patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patton</LastName><ForeName>Michael John</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-5056-6043</Identifier></Author><Author ValidYN="Y"><LastName>Benson</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Robison</LastName><ForeName>Sarah W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Dhaval</LastName><ForeName>Raval</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Locy</LastName><ForeName>Morgan L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Kinner</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Grumley</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Levitan</LastName><ForeName>Emily B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Might</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gaggar</LastName><ForeName>Amit</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Erdmann</LastName><ForeName>Nathaniel</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>JCI Insight. 2024 Apr 23;9(10):e177518. doi: 10.1172/jci.insight.177518</RefSource><PMID Version="1">38652535</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38405753</ArticleId><ArticleId IdType="pmc">PMC10888999</ArticleId><ArticleId IdType="doi">10.1101/2024.02.13.24302781</ArticleId><ArticleId IdType="pii">2024.02.13.24302781</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>